Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Código QR

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Immunotherapy is a new and very promising method of anti-cancer treatment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based on PD-L1 expression and the performance status assessed with the use of Eastern Cooperativ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Damian Mojsak, Beata Kuklińska, Michał Dębczyński, Robert Marek Mróz
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2021
Materias:	non-small cell lung cancer immunotherapy performance status. Medicine R
Acceso en línea:	https://doaj.org/article/33951a72defa418a95258e7273536311
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Takuma Imakita, et al.
Publicado: (2021)

Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy
por: Chenlu Li, et al.
Publicado: (2021)

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
por: Shijie Shang, et al.
Publicado: (2021)

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
por: Gaurav Garg, et al.
Publicado: (2021)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
por: Yahua Wu, et al.
Publicado: (2022)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer
por: Zhihui Zhang, et al.
Publicado: (2021)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu N, et al.
Publicado: (2017)

Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
por: Ting Yoon Kwan, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
por: Valerio Nardone, et al.
Publicado: (2021)

ANTIBODIES TO BENZO[A]PYRENE IN SERUM OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
por: E. G. Polenok, et al.
Publicado: (2012)

Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
por: Puja Shahrouki, MD, et al.
Publicado: (2021)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety D
Publicado: (2019)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Anwen Xiong, et al.
Publicado: (2021)

Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
por: Denis I. Yudin, et al.
Publicado: (2021)

Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report
por: Li Y, et al.
Publicado: (2021)

Research on the application of uniportal video-assisted thoracoscopic segmental resection of the lung in elderly patients with non-small cell lung cancer aged over 65 years
por: Hongya Xie, et al.
Publicado: (2021)

Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
por: Zengfu Zhang, et al.
Publicado: (2021)

Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer
por: Sarah Maryon Hayes, et al.
Publicado: (2021)

Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
por: Tiziana Vavalà, et al.
Publicado: (2021)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo Geng-wei, et al.
Publicado: (2021)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
por: Galina B. Statsenko, et al.
Publicado: (2020)

<i>STK11/LKB1</i> Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
por: Elvire Pons-Tostivint, et al.
Publicado: (2021)

Prospects for the development of adjuvant therapy for non-small cell lung cancer
por: K. K. Laktionov, et al.
Publicado: (2020)

Oligometastatic non-small-cell lung cancer: current treatment strategies
por: Richard PJ, et al.
Publicado: (2016)

Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
por: Elena V. Reutova, et al.
Publicado: (2021)

Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer
por: Ying Liu, et al.
Publicado: (2022)

Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
por: Yang Teng, et al.
Publicado: (2021)

Treatment of advanced small cell lung cancer. Clinical case and literature review
por: Konstantin V. Menshikov, et al.
Publicado: (2021)

Preliminary comparison of neuropsychological performance in patients with non-small-cell lung cancer treated with chemotherapy or targeted therapy
por: Kang HL, et al.
Publicado: (2019)

Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
por: Wenxiao Jiang, et al.
Publicado: (2021)

Untargeted Lipidomics of Non-Small Cell Lung Carcinoma Demonstrates Differentially Abundant Lipid Classes in Cancer vs. Non-Cancer Tissue
por: Joshua M. Mitchell, et al.
Publicado: (2021)

Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer
por: Song X, et al.
Publicado: (2017)

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
por: Diao WY, et al.
Publicado: (2021)

Application of Multifunctional Targeting Epirubicin Liposomes in the Treatment of Non-Small-Cell Lung Cancer [Corrigendum]
por: Song X, et al.
Publicado: (2021)

Analysis of the nuclear localization signal of TRF1 in non-small cell lung cancer
por: JIAN,HU, et al.
Publicado: (2009)

Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies
por: Thierry Berghmans, et al.
Publicado: (2021)

Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
por: Eva Obermayr, et al.
Publicado: (2021)